Recherchiere Firmenbekanntmachungen und finanzielle Kennzahlen
EU-Förderung (1.199.125 €): Effiziente Vernetzung der europäischen Neurodegeneration-Forschung Hor01.03.2019 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
Effiziente Vernetzung der europäischen Neurodegeneration-Forschung
The main aim of NEURONET is to set up an efficient platform to boost synergy and collaboration across the IMI projects of the Neurodegenerative Disorders (ND) portfolio, assisting in identifying gaps, multiplying its impact, enhancing its visibility and facilitating dovetailing with related initiatives in Europe and worldwide. This will be achieved through the following specific objectives: 1) creation of an overall platform for efficient collaboration, communication and operational synergies among present and future IMI ND projects; 2) designing systems to map and analyse information regarding actions, initiatives and partnerships, assessing impact of the individual projects, remaining gaps and global value of the programme for stakeholders; 3) supporting the management of the programme (timelines, dependencies, synergies and key results across projects); 4) proactively detecting needs, opportunities and transferable best practices of projects and to connect them; 5) providing support to the projects by organising tools, services, expert advice and guidelines/recommendations on common issues; 6) promoting enhancement and coordination of communication across the IMI neurodegeneration projects, increasing programme visibility, outreaching to key stakeholders and establishing relationships with initiatives in the field; and 7) preparing and securing the long-term sustainability of NEURONET itself. Achievement of these objectives will necessarily rely on buy-in from existing and future projects in the IMI ND portfolio, and effective connections with other programmes and initiatives in Europe and beyond, including stakeholder representation. For this, the Consortium has been constituted by very active partners in a variety of IMI ND projects and related initiatives with specialists in areas like complex/project management, data sharing & re-use, drug development, patient engagement, communication, sustainability and regulatory/HTA interactions.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Alzheimer Europe | 368.115 € |
| Eli Lilly and Company Ltd. | 0,00 € |
| F. HOFFMANN-LA ROCHE AG | 0,00 € |
| Janssen Pharmaceutica N.V. | 0,00 € |
| 355.538 € | |
| 0,00 € | |
| Sanofi-Aventis Recherche & Developpement | 0,00 € |
| Synapse Research Management Partners SL | 475.472 € |
| TAKEDA PHARMACEUTICALS INTERNATIONAL AG | 0,00 € |
| Takeda Development Centre Europe Ltd. | 0,00 € |
Quelle: https://cordis.europa.eu/project/id/821513
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.
Die Visualisierungen zu "Alzheimer Europe - EU-Förderung (1.199.125 €): Effiziente Vernetzung der europäischen Neurodegeneration-Forschung"
werden von
North Data
zur Weiterverwendung unter einer
Creative Commons Lizenz
zur Verfügung gestellt.
